Citations

Clear

4847 citation(s) found for "Yu, Eric".

Clinical Phenotype of Tardive Dyskinesia in Bipolar Disorder
Gardea-Resendez, Manuel, Taylor-Desir, Monica J., Romo-Nava, Francisco, Bond, David, Vallender, Eric J., Cuellar-Barboza, Alfredo B., Prieto, Miguel L., Nunez, Nicolas, Veldic, Marin, Ozerdem, Aysegul, Singh, Balwinder, Markota, Matej, Colby, Colin L., Coombes, Brandon J., Biernacka, Joanna M., McElroy, Susan L., Frye, Mark A., Singh, Balwinder , Bond, David J. , Özerdem, Ayşegül , Romo‐Nava, Francisco , Gardea‐Resendez, Manuel , Romo-Nava, F , Bond, David J , Singh, Balwinder , Ozerdem, Aysegul , Gardea-Resendez, Manuel , Taylor-Desir, Monica J., Vallender, Eric J., Cuellar-Barboza, Alfredo B., Prieto, Miguel L., Nunez, Nicolas, Veldic, Marin, Singh, Balwinder, Markota, Matej, Colby, Colin L., Coombes, Brandon J., Biernacka, Joanna M., McElroy, Susan L., Frye, Mark A.

Mayo Clinic

Journal of Clinical Psychopharmacology | May 31, 2022 | Volume: 42 | Issue: 2 | Pages: 159-162

10.1097/jcp.0000000000001532 | PMID 35230047 Get It

Abstract Purpose Recognizing the negative impact that antipsychotic-induced movement disorders have on the quality of life and treatment outcomes in bipolar disorder (BD), this study aimed to assess clinical correlates and antipsychotic use patterns of tardive dyskinesia (TD+) in BD. Materials and Methods Participants with and without TD were included. Clinical variables were compared using t-test and χ2 test. Antipsychotic use patterns in TD+, including number of trials, mean doses, and estimated cumulative exposure, were assessed in a case-only analysis. Results The prevalence rate of TD was 5.1%. In comparison to the TD− group (n = 1074), TD+ participants (n = 58) were older, more likely to be female and have type I bipolar illness. There were 60.3% of the TD+ group that continued using antipsychotics at study entry and had a mean cumulative exposure to antipsychotics of 18.2 ± 15.6 years. Average dose, in haloperidol equivalents, was 5.9 ± 3.5 mg and 77.7% of the trials were second-generation antipsychotics. Conclusions This study confirms previously identified TD risk factors, such as age, sex, and bipolar subtype in a large BD cohort. Limitations included a cross-sectional design and the lack of tardive illness severity assessment. As atypical antipsychotics continue to be primary mood stabilization treatment, attempting to harmonize large data sets to identify additional biomarkers of tardive risk will optimize individualized care for patients with BD.
Utilization of Antitumor Necrosis Factor Biologics in Very Early Onset Inflammatory Bowel Disease
Kerur, Basavaraj , Fiedler, Karoline , Stahl, Marisa G. , Hyams, Jeffrey S. , Stephens, Michael C., Lu, Ying , Pfefferkorn, Marian, Alkhouri, Raza, Strople, Jennifer , Kelsen, Judith R. , Siebold, Leah, Goyal, Alka , Rosh, Joel R. , LeLeiko, Neal S. , Limbergen, Johan Van , Maltz, Ross , Karam, Lina , Heyman, Melvin B. , Benkov, Keith , Noe, Joshua D. , Moulton, Dedrick E., Pappa, Helen, Galanko, Joseph A. , Muise, Aleixo M. , Stephens, Michael, Leleiko, Neal S , Guerrerio, Anthony L. , Crowley, Eileen , Griffiths, Anne Marie , Deneau, Mark , Snapper, Scott B. , Kappelman, Michael D. , Benchimol, Eric I.

Mayo Clinic

Journal of Pediatric Gastroenterology and Nutrition | May 27, 2022 | Volume: 75 | Issue: 1 | Pages: 64-69

10.1097/mpg.0000000000003464 | PMID 35622080 Get It

Background:Research on the utilization and effectiveness of antitumor necrosis factor (TNF) biologics in children with very early onset inflammatory bowel disease (VEOIBD) is urgently needed. Here we describe anti‐TNF use and durability in a multicenter cohort.Methods:We performed a retrospective cohort study of patients diagnosed with VEOIBD (<6 years) between 2008 and 2013 at 25 North American centers. We performed chart abstraction at diagnosis and 1, 3, and 5 years after diagnosis. We examined the rate of initiation and durability of infliximab and adalimumab and evaluated associations between treatment durability and the following covariates with multivariate Cox proportional hazard regression: age at diagnosis, sex, disease duration, disease classification, and presence of combined immunomodulatory treatment versus monotherapy.Results:Of 294 children with VEOIBD, 120 initiated treatment with anti‐TNF therapy and 101 had follow‐up data recorded [50% Crohn disease (CD), 31% ulcerative colitis (UC), and 19% IBD unclassified (IBD‐U)]. The cumulative probability of anti‐TNF treatment was 15% at 1 year, 30% at 3 years, and 45% at 5 years from diagnosis; 56 (55%) were treated between 0 and 6 years old. Anti‐TNF durability was 90% at 1 year, 75% at 3 years, and 55% at 5 years. The most common reason for discontinuation of anti‐TNF were loss of response in 24 (57%) children. Children with UC/IBD‐U had lower durability than those with CD (hazard ratio [HR] 0.17; 95% confidence interval [CI], 0.06–0.51; P = 0.001).Conclusions:Utilization and durability of anti‐TNF in VEOIBD is relatively high and comparable with older children. Having Crohn disease (compared with UC/IBD‐U) is associated with greater durability.
Looking ahead: giant-cell arteritis in 10 years time
Bond, Milena , Tomelleri, Alessandro , Buttgereit, Frank , Matteson, Eric L. , Dejaco, Christian , Dejaco, Christian , Buttgereit, Frank

Mayo Clinic

Therapeutic Advances in Musculoskeletal Disease | May 25, 2022 | Volume: 14 | Issue: No issue available | Pages: No page available

10.1177/1759720x221096366 | PMID 35634351 Get It

Although great improvements have been achieved in the fields of diagnosing and treating patients with giant-cell arteritis (GCA) in the last decades, several questions remain unanswered. The progressive increase in the number of older people, together with growing awareness of the disease and use of advanced diagnostic tools by healthcare professionals, foretells a possible increase in both prevalence and number of newly diagnosed patients with GCA in the coming years. A thorough clarification of pathogenetic mechanisms and a better definition of clinical subsets are the first steps toward a better understanding of the disease and, subsequently, toward a better use of existing and future therapeutic options. Examination of the role of different imaging techniques for GCA diagnosing and monitoring, optimization, and personalization of glucocorticoids and other immunosuppressive agents, further development and introduction of novel drugs, identification of prognostic factors for long-term outcomes and management of treatment discontinuation will be the central topics of the research agenda in years to come.
Risk-Based Lung Cancer Screening in the Mayo Clinic Lung Screening Program
Midthun, David E. , Sykes, Anne Marie G., Ingalls, Lori A, Deetz, Daniel C, Degen, Susanne C, Glantz, Janel N, Taji, Jamil, Swanson, Kirsten, Jensen, Eric A., Pappagallo, Laura C, Johnson, Margaret M. , McComb, Barbara L., Loosbrock, Lynn M., Rode, Matthew M. , Allen, Mark S. , Deetz, Daniel C., Degen, Susanne C., Glantz, Janel N., Yang, Ping

Mayo Clinic

B30. THE QUEST FOR THE HOLY GRAIL: MODELING AND BIOMARKERS FOR NODULES AND LUNG CANCER | May 24, 2022 | Volume: No volume available | Issue: No issue available | Pages: A5587-A5587

10.1164/ajrccm-conference.2022.205.1_meetingabstracts.a5587 Get It

Pattern and implications of neurological examination findings in autosomal dominant Alzheimer disease
Vöglein, Jonathan , Morris, John C. , Dieterich, Marianne , Preische, Oliver, Hofmann, Anna, Hassenstab, Jason , Fagan, Anne M. , Noble, James M. , Berman, Sarah , Graff‐Radford, Neill R. , Farlow, Martin R. , Chhatwal, Jasmeer P. , Salloway, Stephen , Xiong, Chengjie , Cairns, Nigel J., Perrin, Richard J. , Day, Gregory S. , Mori, Hiroshi , Suzuki, Kazushi , Masters, Colin L. , Goate, Alison , Buckles, Virginia, Fox, Nick C. , Chrem, Patricio, Ringman, John M. , Yakushev, Igor , Laske, Christoph , Bateman, Randall J. , Network, for the Dominantly Inherited Alzheimer, Day, Gregory S , Bateman, Randall J , Masters, Colin L , Vöglein, Jonathan , Xiong, Chengjie , Fox, Nick C , Hassenstab, Jason , Morris, John C , Goate, Alison M , Berman, Sarah , Noble, James M , Franzmeier, Nicolai , McDade, Eric , Simons, Mikael , Benzinger, Tammie L.S. , Ghetti, Bernardino , Xiong, Chengjie , Karch, Celeste M. , Martins, Ralph N. , Sánchez‐Valle, Raquel , Shimada, Hiroyuki , Ikeuchi, Takeshi , Schofield, Peter R. , Allegri, Ricardo , Jucker, Mathias , Höglinger, Günter U. , Danek, Adrian , Network, for the Dominantly Inherited Alzheimer

Mayo Clinic

Alzheimer's & Dementia | May 24, 2022 | Volume: 19 | Issue: 2 | Pages: 632-645

10.1002/alz.12684 | PMID 35609137 Get It

AbstractIntroductionAs knowledge about neurological examination findings in autosomal dominant Alzheimer disease (ADAD) is incomplete, we aimed to determine the frequency and significance of neurological examination findings in ADAD.MethodsFrequencies of neurological examination findings were compared between symptomatic mutation carriers and non mutation carriers from the Dominantly Inherited Alzheimer Network (DIAN) to define AD neurological examination findings. AD neurological examination findings were analyzed regarding frequency, association with and predictive value regarding cognitive decline, and association with brain atrophy in symptomatic mutation carriers.ResultsAD neurological examination findings included abnormal deep tendon reflexes, gait disturbance, pathological cranial nerve examination findings, tremor, abnormal finger to nose and heel to shin testing, and compromised motor strength. The frequency of AD neurological examination findings was 65.1%. Cross‐sectionally, mutation carriers with AD neurological examination findings showed a more than two‐fold faster cognitive decline and had greater parieto‐temporal atrophy, including hippocampal atrophy. Longitudinally, AD neurological examination findings predicted a significantly greater decline over time.DiscussionADAD features a distinct pattern of neurological examination findings that is useful to estimate prognosis and may inform clinical care and therapeutic trial designs.
MDACT: A New Principle of Adjunctive Cancer Treatment Using Combinations of Multiple Repurposed Drugs, with an Example Regimen
Kast, Richard E. , Alfieri, Alex , Assi, Hazem , Elyamany, Ashraf , González‐Cao, María , Karpel‐Massler, Georg , Marosi, Christine , Salacz, Michael, Sardi, Iacopo , Vlierberghe, Pieter Van , Zaghloul, Mohamed S. , Halatsch, Marc‐Eric , Assi, Hazem I , Elyamany, Ashraf M , Gonzalez-Cao, Maria , Sardi, Iacopo , Van Vlierberghe, Pieter , Zaghloul, Mohamed S , Halatsch, Marc-Eric , Burns, Terry C.

Mayo Clinic

Cancers | May 23, 2022 | Volume: 14 | Issue: 10 | Pages: 2563

10.3390/cancers14102563 | PMID 35626167 Get It

In part one of this two-part paper, we present eight principles that we believe must be considered for more effective treatment of the currently incurable cancers. These are addressed by multidrug adjunctive cancer treatment (MDACT), which uses multiple repurposed non-oncology drugs, not primarily to kill malignant cells, but rather to reduce the malignant cells’ growth drives. Previous multidrug regimens have used MDACT principles, e.g., the CUSP9v3 glioblastoma treatment. MDACT is an amalgam of (1) the principle that to be effective in stopping a chain of events leading to an undesired outcome, one must break more than one link; (2) the principle of Palmer et al. of achieving fractional cancer cell killing via multiple drugs with independent mechanisms of action; (3) the principle of shaping versus decisive operations, both being required for successful cancer treatment; (4) an idea adapted from Chow et al., of using multiple cytotoxic medicines at low doses; (5) the idea behind CUSP9v3, using many non-oncology CNS-penetrant drugs from general medical practice, repurposed to block tumor survival paths; (6) the concept from chess that every move creates weaknesses and strengths; (7) the principle of mass—by adding force to a given effort, the chances of achieving the goal increase; and (8) the principle of blocking parallel signaling pathways. Part two gives an example MDACT regimen, gMDACT, which uses six repurposed drugs—celecoxib, dapsone, disulfiram, itraconazole, pyrimethamine, and telmisartan—to interfere with growth-driving elements common to cholangiocarcinoma, colon adenocarcinoma, glioblastoma, and non-small-cell lung cancer. gMDACT is another example of—not a replacement for—previous multidrug regimens already in clinical use, such as CUSP9v3. MDACT regimens are designed as adjuvants to be used with cytotoxic drugs.
TNF blockade enhances the efficacy of myxoma virus-based oncolytic virotherapy
Valenzuela-Cardenas, Miriam , Gowan, Cody, Dryja, Parker, Bartee, Mee Y., Bartee, Eric

Mayo Clinic

Journal for ImmunoTherapy of Cancer | May 23, 2022 | Volume: 10 | Issue: 5 | Pages: e004770

10.1136/jitc-2022-004770 | PMID 35577502 Get It

Background Oncolytic virotherapy (OV) represents a method to treat a variety of solid tumors by inducing antitumor immune responses. While this therapy has been extremely efficacious in preclinical models, translating these successes into human patients has proven challenging. One of the major reasons for these failures is the existence of immune-regulatory mechanisms, which dampen the efficacy of virally induced antitumor immunity. Unfortunately, the full extent of these immune-regulatory pathways remains unclear. Methods To address this issue, we generated a doubly recombinant, oncolytic myxoma virus which expresses both a soluble fragment of programmed cell death protein 1 (PD1) and an interleukin 12 (IL-12) fusion protein (vPD1/IL-12 (virus-expressing PD1 and IL-12)). We then tested the molecular impact and therapeutic efficacy of this construct in multiple models of disseminated disease to identify novel pathways, which are associated with poor therapeutic outcomes. Results Our results demonstrate that vPD1/IL-12 causes robust inflammation during therapy including inducing high levels of tumor necrosis factor (TNF). Surprisingly, although expression of TNF has generally been assumed to be beneficial to OV, the presence of this TNF appears to inhibit therapeutic efficacy by reducing intratumoral T-cell viability. Likely because of this, disruption of the TNF pathway, either through genetic knockout or antibody-based blockade, significantly enhances the overall outcomes of vPD1/IL-12-based therapy that allows for the generation of complete cures in normally non-responsive models. Conclusions These data suggest that some aspects of OV-induced inflammation might represent a double-edged sword during therapy and that specific blockade of TNF might enhance the efficacy of these treatments.
Comparative Performance of Different Respiratory Test Parameters for Detection of Early Respiratory Insufficiency in Patients With ALS
Kelly, Cecilia R. , Parra‐Cantu, Carolina , Thapa, Prabin , Boynton, Bradley, Selim, Bernardo J., Sorenson, Eric J. , Martinez‐Thompson, Jennifer M. , Mandrekar, Jaywant, Staff, Nathan P. , Staff, Nathan P

Mayo Clinic

Neurology | May 23, 2022 | Volume: 99 | Issue: 7 | Pages: No page available

10.1212/wnl.0000000000200758 | PMID 35584920 Get It

Performing parotidectomy postoperative follow-ups via telemedicine: Experience at a tertiary care, multiple-surgeon otolaryngology center
Antezana, Luis A. , Xie, Katherine , Bowen, Andrew J, Yeakel, Sarah, Nassiri, Ashley M. , Moore, Eric J. , Xie, Katherine Z , Antezana, Luis , Yin, Linda X. , Bowen, Andrew J

Mayo Clinic

Journal of Telemedicine and Telecare | May 18, 2022 | Volume: 30 | Issue: 4 | Pages: 739-746

10.1177/1357633x221095319 | PMID 35549759 Get It

Introduction We examined the suitability of using a video visit platform to perform postoperative parotidectomy evaluation at a tertiary care, multiple-surgeon otolaryngology center. Methods A retrospective case review was conducted of patients who underwent parotidectomy and postoperative video visits between November 2019 and December 2020. Success of video visit, plan if applicable, and post-visit outcomes were reviewed. Video visits were designated as successful if the physician could assess for complications in the postoperative course (e.g. first bite pain, Frey syndrome, ear numbness, unplanned visits to the emergency department, unplanned return to the operating room), perform examination of facial nerve function, and formulate care recommendations per clinical judgement without deferment of recommendations for a subsequent in-person visit. Results There were 96 postoperative video visits with 91 unique parotidectomy patients. Demographics: 28/63 male/female; average age, 54y. All video visits were suitable for successful postoperative parotidectomy patient evaluation. Eight visits (8.3%) consisted of patients presenting with common postoperative complications (e.g. eye dryness, first bite pain) and warranted care recommendations. In only two cases did the patient require further in-person procedural (hematoma evacuation, seroma aspiration) follow-ups. For the other 91.7% of visits (n = 88), no additional recommendations were required as patients experienced uncomplicated postoperative courses. Of all the patients, 26.1% (n = 23) were instructed to follow-up for routine surveillance. All other patients, 73.9% (n = 65) were instructed to follow-up as needed. Conclusion Postoperative parotidectomy evaluation is highly amenable to being performed by video. A telemedicine option offers convenience for patients in the majority of cases without compromising clinical assessment and judgment for the physician.